KMT2A and acute lymphoblastic leukemia: Hence, while promising clinical trials testing the efficacy of Menin inhibition [16] (NCT04067336) or immunotherapies, e.g., Blinatumomab (NTR6359) and CAR-T cells [17], against KMT2A-rearranged infant ALL are being initiated, readily available and effective therapeutic alternatives to standard combination chemotherapy hardly exist.